title: DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation.
abstract: CDA-II (cell differentiation agent II), isolated from healthy human urine, is a DNA methyltransferase inhibitor. Previous studies indicated that CDA-II played important roles in the regulation of cell growth and certain differentiation processes. However, it has not been determined whether CDA-II affects skeletal myogenesis. In this study, we investigated effects of CDA-II treatment on skeletal muscle progenitor cell differentiation, migration and proliferation. We found that CDA-II blocked differentiation of murine myoblasts C2C12 in a dose-dependent manner. CDA-II repressed expression of muscle transcription factors, such as Myogenin and Mef2c, and structural proteins, such as myosin heavy chain (Myh3), light chain (Mylpf) and MCK. Moreover, CDA-II inhibited C1C12 cell migration and proliferation. Thus, our data provide the first evidence that CDA-II inhibits growth and differentiation of muscle progenitor cells, suggesting that the use of CDA-II might affect skeletal muscle functions.
authors.affiliation: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China.
authors.forename: Zirong
authors.initials: Z
authors.lastname: Chen
authors.forename: Guorong
authors.initials: G
authors.lastname: Jin
authors.forename: Shuibin
authors.initials: S
authors.lastname: Lin
authors.forename: Xiumei
authors.initials: X
authors.lastname: Lin
authors.forename: Yumei
authors.initials: Y
authors.lastname: Gu
authors.forename: Yujuan
authors.initials: Y
authors.lastname: Zhu
authors.forename: Chengbin
authors.initials: C
authors.lastname: Hu
authors.forename: Qingjiong
authors.initials: Q
authors.lastname: Zhang
authors.forename: Lizi
authors.initials: L
authors.lastname: Wu
authors.forename: Huangxuan
authors.initials: H
authors.lastname: Shen
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D015870:Gene Expression / Q000187:drug effects; D064326:MEF2 Transcription Factors; D051379:Mice; D024510:Muscle Development / Q000187:drug effects* / Q000235:genetics; D032446:Myoblasts / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D032448:Myoblasts, Skeletal / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D018006:Myogenic Regulatory Factors / Q000037:antagonists & inhibitors; D018008:Myogenin / Q000037:antagonists & inhibitors; D018995:Myosin Heavy Chains / Q000037:antagonists & inhibitors; D010455:Peptides / Q000494:pharmacology*; D010648:Phenylacetates / Q000494:pharmacology*
chemical_list: D064326:MEF2 Transcription Factors; C578041:Mef2c protein, mouse; D018006:Myogenic Regulatory Factors; D018008:Myogenin; D010455:Peptides; D010648:Phenylacetates; C480340:cell differentiation agent II; D015254:DNA Modification Methylases; D018995:Myosin Heavy Chains